Capricor Therapeutics, Inc. (CAPR) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
CAPR Revenue Growth
CAPR Revenue Analysis (2013–2024)
As of May 8, 2026, Capricor Therapeutics, Inc. (CAPR) generated trailing twelve-month (TTM) revenue of $11.1 million, reflecting significant decline in growth of -100.0% year-over-year. The most recent quarter (Q3 2025) recorded $0 in revenue.
Looking at the longer-term picture, CAPR's 5-year compound annual growth rate (CAGR) stands at +85.8%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $25.2 million in 2023.
When compared to Healthcare sector peers including SRPT (-2.2% YoY), CRSP (-88.9% YoY), and EXEL (+3.3% YoY), CAPR has underperformed the peer group in terms of revenue growth. Compare CAPR vs SRPT →
CAPR Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CAPRCurrent | $11M | -100.0% | +85.8% | -191.1% | |
 SRPT | $2.2B | -2.2% | +32.4% | -29.9% | |
 CRSP | $4M | -88.9% | +37.3% | -16191.4% | |
 EXEL | $2.3B | +3.3% | +18.6% | 37.6% | |
 FOLD | $634M | +20.0% | +19.4% | 5.4% | |
 RARE | $673M | +13.3% | +19.9% | -79.5% |
CAPR Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $22.3M | -11.5% | $-27,698,120 | -124.4% | $-42,564,842 | -191.1% |
| 2023 | $25.2M | +886.8% | $-11,269,973 | -44.8% | $-24,077,859 | -95.6% |
| 2022 | $2.6M | +941.8% | $-19,265,480 | -755.1% | $-29,697,383 | -1163.9% |
| 2021 | $245K | -21.1% | $245K | 100.0% | $-20,938,442 | -8549.9% |
| 2020 | $310K | -69.1% | $310K | 100.0% | $-13,689,971 | -4412.6% |
| 2019 | $1.0M | -39.9% | $-4,136,777 | -411.6% | $-7,733,888 | -769.5% |
| 2018 | $1.7M | -37.3% | $1.7M | 100.0% | $-15,327,000 | -917.2% |
| 2017 | $2.7M | -16.4% | $2.7M | 100.0% | $-12,862,000 | -482.4% |
| 2016 | $3.2M | -15.5% | $-12,043,000 | -377.5% | $-16,977,000 | -532.2% |
| 2015 | $3.8M | -9.4% | $-8,240,000 | -218.2% | $-12,612,000 | -334.0% |
See CAPR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CAPR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CAPR vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCAPR — Frequently Asked Questions
Quick answers to the most common questions about buying CAPR stock.
Is CAPR's revenue growth accelerating or slowing?
CAPR revenue declined -100.0% year-over-year, contrasting with the 5-year CAGR of +85.8%. TTM revenue fell to $11M. This reverses the prior growth trend.
What is CAPR's long-term revenue growth rate?
Capricor Therapeutics, Inc.'s 5-year revenue CAGR of +85.8% reflects the variable expansion pattern. Current YoY growth of -100.0% is below this long-term average.
How is CAPR's revenue distributed by segment?
CAPR reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.